ISO ISOPLEXIS CORP

IsoPlexis to Participate in Three Upcoming Investor Conferences

IsoPlexis to Participate in Three Upcoming Investor Conferences

BRANFORD, Conn., Feb. 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced the company will be participating in the following investor conferences.

  • 11th Annual SVB Leerink Global Healthcare Conference, Virtual

    Fireside Chat on Wednesday, February 16th at 7:00 a.m. Pacific Time / 10:00 a.m. Eastern Time



  • Cowen 42nd Annual Health Care Conference, Virtual

    Fireside Chat on Wednesday, March 9th at 6:10 a.m. Pacific Time / 9:10 a.m. Eastern Time



  • Barclays Global Healthcare Conference

    Fireside Chat on Tuesday, March 15th at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time

Interested parties may access live and archived webcasts on the “Investors” section of the company website at: .

About IsoPlexis

IsoPlexis is the Superhuman Cell company.

IsoPlexis’ systems uniquely identify a comprehensive range of multifunctional single cells, i.e. the superhero cells in the human body. These cells enable researchers to understand and predict disease progression, treatment resistance and therapeutic efficacy to advance all of human health.

IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at two-thirds of leading U.S. comprehensive cancer centers.

Investor Contact



Press Contact



EN
11/02/2022

Underlying

ISOISOPLEXIS CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ISOPLEXIS CORP

 PRESS RELEASE
Free
ISO ISOPLEXIS CORP

IsoPlexis Reports Preliminary Full Year 2022 Revenue

IsoPlexis Reports Preliminary Full Year 2022 Revenue BRANFORD, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full year ended December 31, 2022. Total revenue for the full year ended December 31, 2022 is expected to be in the range of $16.6 to $16.8 million, representing a decrease of approximately 3% to 4% compared to $17.3 million for the full year ended December 31, 2021. Fourth quarter results were l...

January 12, 2023 1 EN
 PRESS RELEASE
Free
ISO ISOPLEXIS CORP

Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Ce...

Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (Nasdaq: BLI), a life sciences tools company, and IsoPlexi...

December 21, 2022 1 EN
 PRESS RELEASE
Free
ISO ISOPLEXIS CORP

IsoPlexis Reports Third Quarter 2022 Financial Results

IsoPlexis Reports Third Quarter 2022 Financial Results BRANFORD, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended September 30, 2022. Recent Highlights Revenue of $4.5 million for the third quarter 2022, representing a 7% increase from the corresponding period of 2021Sold 23 new instruments in the third quarter, bringing cumulative instruments sold to 277Reduced total operating expenses by 27% from the prior...

November 10, 2022 1 EN
 PRESS RELEASE
Free
ISO ISOPLEXIS CORP

IsoPlexis to Participate in Upcoming Investor Conferences

IsoPlexis to Participate in Upcoming Investor Conferences BRANFORD, Conn., Nov. 09, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will be participating in the following investor conferences. Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, New York, NYMulti-Omics Panel on Thursday, November 17th at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time Evercore ISI HealthCONx Conference, VirtualFireside Chat on Thursday, December 1st a...

November 9, 2022 1 EN
 PRESS RELEASE
Free
ISO ISOPLEXIS CORP

IsoPlexis to Report Third Quarter 2022 Financial Results on November 1...

IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022 BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section ...

October 19, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch